InMed Pharmaceuticals (INM) Non Operating Income (2023 - 2024)
InMed Pharmaceuticals' (INM) quarterly Non Operating Income came in at $528120.0 in Q2 2024, up 255.5% year-on-year from $148559.0 in Q3 2023, and up 334.82% quarter-over-quarter from $121458.0 in Q1 2024.
InMed Pharmaceuticals (INM) Non Operating Income (2023 - 2024) Analysis & Trends
InMed Pharmaceuticals' Non Operating Income history runs 2 years deep, the most recent figure standing at $528120.0 for Q2 2024.
- On a quarterly basis, Non Operating Income rose 255.5% year-over-year to $528120.0 in Q2 2024; TTM through Jun 2024 was $953634.0, a N/A change from a year earlier, with the FY2024 full-year figure at $527901.0, up 7.2% from the prior year.
- Non Operating Income grew to $528120.0 in Q2 2024 per INM's latest filing, from $121458.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $528120.0 in Q2 2024 and bottomed at $121458.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -216.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 20.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -7.50 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 53.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | InMed Pharmaceuticals | 307,858.50 | -4.93 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 528,120.00 |
| Mar 31, 2024 | 121,458.00 |
| Jun 30, 2023 | 148,559.00 |
| Mar 31, 2023 | 155,497.00 |